Patient Benefits
- For chronic therapy, optimised bioavailability and reproducible absorption profiles for every dose on every occasion
In acute conditions, faster and more consistent absorption for rapid onset of action - Potential for ultra-high initial plasma concentrations to drive distribution into effect compartments for a reliable therapeutic effect
- Decreased gastric residence time reduces risks of local irritation and toxicity
- Surge Dose® tablets do not rely on the presence of gastric acid so are ideal for achlorhydric patients such as those on PPI
Development Benefits
- Allows for customized release and absorption profiles :
- Single component or fixed dose drug combinations
- Combination of fast and controlled release components
- Maximises therapeutic potential for NMEs by ensuring reproducible and consistent PK even in early development.
- Minimizes need for significant reformulation in later development
- Opportunity for life cycle extension or development of value-add generics for existing drugs
- In vitro non-sink dissolution methodology to optimise formulations and identify lead candidates for clinical evaluation reduces project risks and results in shorter development times and costs
- Technology uses GRAS excipients with conventional RH controlled manufacturing processes and equipment